Latest News

Recent commentary has highlighted Southern Copper Corp (NYSE: SCCO) as a quality candidate, citing its solid financial profile, profitable operations, high capital efficiency, and strong balance sheet as evidence of a resilient business. An interesting angle is that investors appear focused on the company’s top-tier resource portfolio and industry position as potential supports for long-term stability, even as its current valuation is described as high. With this backdrop of financial...

Key Insights Significantly high institutional ownership implies W&T Offshore's stock price is sensitive to their...

Mizuho Financial Group (TSE:8411) has drawn investor attention after a strong recent run, with the share price up over the past month and past 3 months. Let us unpack what today’s valuation reflects. See our latest analysis for Mizuho Financial Group. The recent 14.7% 1 month share price return and 41.1% 3 month share price return suggest momentum has been building, while the 1 year total shareholder return of 74.1% points to a strong longer term payoff for investors who stayed invested. If...

Why the lucerastat data matters for Idorsia shares Idorsia (SWX:IDIA) just put fresh Phase 3 and long term lucerastat data for Fabry disease into the public domain, with kidney and cardiac outcomes now in focus after the study missed its primary pain endpoint. For you as a shareholder or potential investor, this shifts attention to how lucerastat might fit into Idorsia's broader rare disease pipeline, future regulatory discussions, and the perceived value of its R&D portfolio. See our latest...

Red Sea transit puts Maersk’s risk calculus back in focus A.P. Møller - Mærsk (CPSE:MAERSK B) has resumed using the Red Sea Suez Canal route, with the U.S. flag Maersk Denver completing a two day passage. This development is putting operational risk and capacity planning back on investors’ radar. See our latest analysis for A.P. Møller - Mærsk. The return to Red Sea transits comes after a strong period for A.P. Møller - Mærsk’s shares, with a 24.36% 3 month share price return and a 62.86% 1...

If you are wondering whether TJX Companies is still good value after a strong run, this article walks through what the current price really implies for the stock. TJX shares recently closed at US$158.14, with returns of 2.7% over 7 days, 1.3% over 30 days, 2.5% year to date, 34.3% over 1 year, 102.1% over 3 years and 153.5% over 5 years. This raises the question of how much of the story is already reflected in the price. Recent coverage has focused on TJX Companies as a major off price...

Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Amphenol (APH) is back on investors’ radar after recent share price moves, with the stock closing at US$148.97 as the company’s broader return and growth profile draw closer scrutiny. See our latest analysis for Amphenol. Beyond the latest move to US$148.97, Amphenol’s 30 day share price return of 15.27% and 90 day share price return of 18.61% sit alongside a very large 5 year total shareholder return of roughly 4.7x. This points to momentum that has built over time rather than appearing...

If you are wondering whether Invesco’s current share price offers value or is starting to look stretched, you are in the right place for a clear, valuation focused checkup. Invesco’s stock most recently closed at US$28.30, with returns of 0.2% over 7 days, 7.8% over 30 days, 5.0% year to date, 78.2% over 1 year and 70.5% over 3 years. Many investors use these figures as a starting point for judging how sentiment and risk perception may be shifting. Recent attention on Invesco has focused on...

Amicus Therapeutics (FOLD) drew investor attention after recent trading left its shares around $14.32, and returns over the past month and past 3 months outpaced its year-to-date performance. See our latest analysis for Amicus Therapeutics. At a latest share price of $14.32, Amicus Therapeutics has seen its recent momentum build, with a 30 day share price return of 35.73% and a 90 day share price return of 71.09%. Its 1 year total shareholder return of 55.48% contrasts with a more modest 3...

Celanese (CE) has drawn fresh attention after board member Scott Sutton resigned following his appointment as Chief Executive Officer of Rayonier Advanced Materials, raising questions about board composition and future oversight. See our latest analysis for Celanese. While Sutton’s departure has sparked fresh discussion about governance, most of the recent attention on Celanese has centered on its share price. It trades at US$45.88 after a 90 day share price return of 14.16% and an 8.82% year...

Falabella's (SNSE:FALABELLA) stock is up by a considerable 10% over the past three months. Given that the market...

If you are wondering whether Adams Diversified Equity Fund is still good value at around its recent price, this article walks through what the current data can and cannot tell you about that question. The fund's recent returns include a 0.3% decline over the last 7 days, a 3.6% gain over 30 days, 0.4% year to date, 25.8% over 1 year, 104.9% over 3 years, and 118.0% over 5 years, which may shape how investors are thinking about both opportunity and risk right now. Recent coverage around Adams...

IAC (IAC) has drawn investor interest after recent trading left the shares at US$40.20, with returns over the past month and past 3 months contrasting with a longer period of weaker total returns. See our latest analysis for IAC. The recent move to US$40.20 comes after a 4.1% 1 month share price return and a 20.8% 3 month share price return, while the 1 year total shareholder return of 17.2% contrasts with weaker 3 and 5 year total shareholder returns. This suggests momentum has picked up...

Investor interest in BrightSpring Health Services (BTSG) has picked up as favorable analyst sentiment focuses on its role in home and community-based care, highlighting the importance of its Pharmacy Solutions and Provider Services segments. See our latest analysis for BrightSpring Health Services. At a share price of $38.62, BrightSpring’s recent 30 day share price return of 5.69% builds on a 90 day share price return of 25.63%. The 1 year total shareholder return of 116.97% points to strong...

Monster Beverage (MNST) is back in focus after recent trading, with the stock last closing at $78.43. With solid reported revenue and profit figures, investors are reassessing how this beverage group fits into their portfolios. See our latest analysis for Monster Beverage. Recent trading has added to that interest, with a 1 day share price return of 1.20% and a 90 day share price return of 14.25%, while the 1 year total shareholder return of 56.55% points to stronger, longer term momentum. If...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...

In January 2026, Dispatch Bio and CARsgen Therapeutics announced a clinical collaboration in China to start a Phase 1 trial evaluating DISP-11, which combines Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevor-cel in patients with epithelial solid tumors. This alliance is significant because it seeks to adapt a multiple myeloma CAR T-cell therapy for solid tumors, an area where immunotherapies have historically faced major biological...

In recent trading, Seatrium extended its early-January momentum as investors focused on its progress toward resolving a wind-turbine installation vessel dispute with a Maersk affiliate, tied to a planned delivery milestone by 28 February 2026 and an associated upfront payment. The outcome of this vessel handover now stands out as a material test of Seatrium’s ability to protect cash flow and project margins while it pursues further contract wins. We’ll now explore how the anticipated Maersk...

NICE (TASE:NICE) is in focus after AOK Bayern, a major German public health insurer, deployed the NICE CXone platform on the EU Sovereign Cloud to support more than 4.5 million members. See our latest analysis for NICE. The AOK Bayern win arrives after a softer period for NICE’s shares. The latest ₪366.0 price sits alongside a 90 day share price return of 15.38% decline and a 1 year total shareholder return of 40.79% loss, suggesting momentum has been fading even as high profile cloud CX...

If you are wondering whether ACADIA Pharmaceuticals' current share price still offers value after recent moves, this article walks through the numbers so you can judge for yourself. The stock closed at US$26.46, with a 1.8% decline over the last 7 days and a 2.5% decline over 30 days, while its 1 year return sits at 56.6% and its 3 year return at 46.6% against a 50.4% decline over 5 years. These mixed returns over different time frames help explain why some investors see renewed potential...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...